GlassScriptPhysician profile
Robert Allen Beck
NPI 1679543649
$621.72
in general payments reported to CMS, 2019-2025
19 companies · $17.97 in 2025
The $17.97 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $0.83 · 2021: $13.64 · 2023: $34.76 · 2024: $555 · 2025: $17.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81.51 | 2021-2025 | |
| Eisai INC. | $78.74 | 2024 | |
| Mdd US Operations, LLC | $77.74 | 2024 | Gocovri, Apokyn |
| Biogen, INC. | $57.30 | 2024 | Tysabri, Avonex, Vumerity |
| Averitas Pharma INC. | $41.65 | 2024 | Qutenza |
| Abbott Laboratories | $34.76 | 2023 | Infinity |
| Microtransponder, INC. | $32.52 | 2024 | |
| Ucb, INC. | $27.41 | 2024 | Nayzilam |
| Lundbeck LLC | $26.26 | 2024 | Vyepti |
| Banner Life Sciences, LLC | $24.08 | 2024 | |
| Alnylam Pharmaceuticals INC. | $23.61 | 2024 | Amvuttra |
| Ge Healthcare | $19.56 | 2024 | |
| Amgen INC. | $18.27 | 2024 | Uplizna |
| Argenx US, INC. | $16.39 | 2024 | Vyvgart Hytrulo |
| Jazz Pharmaceuticals INC. | $15.92 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.46 | 2024 | |
| Kyowa Kirin, INC. | $15.21 | 2024 | Nourianz |
| Scilex Pharmaceuticals INC. | $14.50 | 2024 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.